Department of Population Sciences, Beckman Research Institute of City of Hope, CA, Duarte, USA.
Formerly, Department of Medical Oncology, City of Hope National Medical Center, Duarte, CA, USA.
J Ovarian Res. 2023 Jul 17;16(1):141. doi: 10.1186/s13048-023-01234-x.
High-grade serous ovarian cancers (HGSCs) display a high degree of complex genetic alterations. In this study, we identified germline and somatic genetic alterations in HGSC and their association with relapse-free and overall survival. Using a targeted capture of 557 genes involved in DNA damage response and PI3K/AKT/mTOR pathways, we conducted next-generation sequencing of DNA from matched blood and tumor tissue from 71 HGSC participants. In addition, we performed the OncoScan assay on tumor DNA from 61 participants to examine somatic copy number alterations (SCNA).
Approximately one-third of tumors had loss-of-function (LOF) germline (18/71, 25.4%) or somatic (7/71, 9.9%) variants in the DNA homologous recombination repair pathway genes BRCA1, BRCA2, CHEK2, MRE11A, BLM, and PALB2. LOF germline variants also were identified in other Fanconi anemia genes and in MAPK and PI3K/AKT/mTOR pathway genes. Most tumors harbored somatic TP53 variants (65/71, 91.5%). Using the OncoScan assay on tumor DNA from 61 participants, we identified focal homozygous deletions in BRCA1, BRCA2, MAP2K4, PTEN, RB1, SLX4, STK11, CREBBP, and NF1. In total, 38% (27/71) of HGSC patients harbored pathogenic variants in DNA homologous recombination repair genes. For patients with multiple tissues from the primary debulking or from multiple surgeries, the somatic mutations were maintained with few newly acquired point mutations suggesting that tumor evolution was not through somatic mutations. There was a significant association of LOF variants in homologous recombination repair pathway genes and high-amplitude somatic copy number alterations. Using GISTIC analysis, we identified NOTCH3, ZNF536, and PIK3R2 in these regions that were significantly associated with an increase in cancer recurrence and a reduction in overall survival.
From 71 patients with HGCS, we performed targeted germline and tumor sequencing and provided a comprehensive analysis of these 557 genes. We identified germline and somatic genetic alterations including somatic copy number alterations and analyzed their associations with relapse-free and overall survival. This single-site long-term follow-up study provides additional information on genetic alterations related to occurrence and outcome of HGSC. Our findings suggest that targeted treatments based on both variant and SCNA profile potentially could improve relapse-free and overall survival.
高级别浆液性卵巢癌(HGSC)表现出高度复杂的遗传改变。在这项研究中,我们鉴定了 HGSC 中的种系和体细胞遗传改变及其与无复发生存和总生存的关系。使用针对涉及 DNA 损伤反应和 PI3K/AKT/mTOR 途径的 557 个基因的靶向捕获,我们对 71 名 HGSC 参与者的匹配血液和肿瘤组织中的 DNA 进行了下一代测序。此外,我们对 61 名参与者的肿瘤 DNA 进行了 OncoScan 检测,以检查体细胞拷贝数改变(SCNA)。
大约三分之一的肿瘤存在 DNA 同源重组修复途径基因 BRCA1、BRCA2、CHEK2、MRE11A、BLM 和 PALB2 的失活(LOF)种系(18/71,25.4%)或体细胞(7/71,9.9%)变体。在其他范可尼贫血基因和 MAPK 和 PI3K/AKT/mTOR 途径基因中也发现了 LOF 种系变体。大多数肿瘤存在体细胞 TP53 变体(65/71,91.5%)。使用 61 名参与者的肿瘤 DNA 的 OncoScan 检测,我们鉴定出 BRCA1、BRCA2、MAP2K4、PTEN、RB1、SLX4、STK11、CREBBP 和 NF1 中的局灶性纯合性缺失。总的来说,71 名 HGSC 患者中有 38%(27/71)存在 DNA 同源重组修复基因的致病性变体。对于具有原发性减瘤术或多次手术的多个组织的患者,体细胞突变得以维持,很少有新获得的点突变,表明肿瘤进化不是通过体细胞突变。同源重组修复途径基因的 LOF 变体与高振幅体细胞拷贝数改变之间存在显著关联。使用 GISTIC 分析,我们在这些区域鉴定出 NOTCH3、ZNF536 和 PIK3R2,它们与癌症复发增加和总生存减少显著相关。
从 71 名 HGCS 患者中,我们进行了靶向种系和肿瘤测序,并对这 557 个基因进行了全面分析。我们鉴定了种系和体细胞遗传改变,包括体细胞拷贝数改变,并分析了它们与无复发生存和总生存的关系。这项单站点长期随访研究提供了与 HGSC 发生和结局相关的遗传改变的附加信息。我们的发现表明,基于变体和 SCNA 谱的靶向治疗可能改善无复发生存和总生存。